ANI Pharmaceuticals has championed its “superior R&D capabilities” after launching the first US generic version of Takeda’s Motegrity (prucalopride) tablets.
The US firm’s launch – via its Novitium Pharma subsidiary – of the serotonin-4 receptor agonist for adult chronic...